StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
FULCFulcrum Therapeutics, Inc.
stockpulse.co.kr
Nasdaq
$3.67▼ 0.27%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $244.5MShares out 66.6M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

13
  • 4d agoAfter-hours26.10.21 06:09
    S-4/AOffering#●●●#●●●#●●●

    Fulcrum Therapeutics, Inc.

    Fulcrum Therapeutics has entered into a definitive merger agreement with Slate Medicines, with the combined company to be renamed Slate Medicines, Inc. and trade on Nasdaq under the ticker 'SLTE'. In connection with the merger, Slate will raise approximately $245 million in a concurrent investment, and pre-merger Fulcrum stockholders are expected to own approximately 5.0% of the combined entity.…more

    $3.67-0.27%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 10.8After-hours26.10.09 06:10
    S-4/AOffering

    Fulcrum Therapeutics, Inc.

    Fulcrum Therapeutics has finalized a merger agreement with Slate Medicines and will pay a pre-closing special cash dividend of approximately $270 million to its shareholders. Upon completion of the merger, the company will be renamed Slate Medicines, Inc. and is expected to trade on Nasdaq under the ticker symbol SLTE. Fulcrum will also hold a special meeting of stockholders to approve a reverse stock split and the issuance of new shares.…more

    $3.67-0.27%vs prev close
    View filingShare
  • 9.2Regular26.09.02 22:30
    144Ownership

    Fulcrum Therapeutics, Inc.

    Fulcrum Therapeutics insider Greg Tourangeau has filed SEC Form 144 to report a proposed sale of company securities. This filing formalizes the insider's plan to dispose of their holdings, indicating that a stock sale is scheduled to occur.…more

    $3.67-0.27%vs prev close
    View filingShare

12 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 8.17Pre-market26.08.17 20:00
    Bullish#●●●#●●●

    Fulcrum Therapeutics to Merge with Slate Medicines and Raise $245M

    Fulcrum Therapeutics will merge with migraine-focused biotech Slate Medicines, securing $245 million in private placement financing to fund operations through 2029. The combined entity will operate as Slate Medicines and prioritize the advancement of its clinical-stage migraine therapy pipeline.…more

    $3.67-0.27%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    Read sourceShareGlobeNewswire